Chadi Nabhan, MD, MBA, FACP is an innovative Physician Executive and leader in driving transformational changes in healthcare.
Prior to joining Aptitude Health, Dr. Nabhan served as the Vice President and Chief Medical Officer at Cardinal Health, and Medical Director of the Clinical Cancer Center at the University of Chicago where he oversaw the clinical operations of cancer clinics supervising medical, surgical, and radiation oncology. He was instrumental in obtaining the QOPI certification for the University of Chicago and an integral member of the team implementing clinical care pathways.
Prior to his tenure at the University of Chicago, Dr. Nabhan was the Director and Chief of the Division
of Hematology and Oncology at the Advocate Lutheran General Hospital in Park ridge, IL. In addition,
he was the Medical Director of the Cancer Institute at Advocate Lutheran leading strategic and
marketing efforts for the cancer service line.
Dr. Nabhan is a hematologist and medical oncologist with special interest in malignant hematology
and GU malignancies. He has been the primary investigator on many clinical trials, and some of his
research work has been presented at national and international meetings. He also has an interest in
Double Hit Lymphomas and serves on the Double Hit Lymphoma Foundation Board. Dr. Nabhan has
more than 200 peer-reviewed articles, abstracts or book chapters and serves on editorial boards of
multiple scientific journals, including JAMA-Oncology. He is also a reviewer for major medical
journals, including: JAMA, JAMA-Oncology, Blood, Annals of Oncology, European Journal of
Hematology, and British Journal of Hematology. In addition, Dr. Nabhan is interested in developing
strategies to improve cancer care delivery in an era where reimbursement models are rapidly
changing; he has a focus on the business and economic aspect of oncology care as they impact all
Dr. Nabhan maintains his licenses to practice in the states of IL, IN, WI, FL, and CA. He is a highly
sought-after speaker and moderator by all stakeholders on cancer-related and medical business